+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating whether skipping additional axillary treatment for patients with early-stage breast cancer who had cancer in their lymph nodes before chemotherapy but show no remaining cancer in those nodes after treatment is as effective as the standard approach. This study focuses on disease-free survival and reducing the risk of lymphoedema five years after treatment. It is a randomized, open, multicenter trial including patients with specific breast cancer stages and confirmed nodal metastases. Participants will all receive standard therapies including HER2-targeted treatment, endocrine therapy, and radiotherapy to the breast or chest wall if needed. They will be randomly assigned to one of two groups one group will not get further axillary treatment such as lymph node removal or radiotherapy, while the other group will receive these axillary treatments according to local guidelines. Follow-up visits will occur annually for at least five years. During the study, participants will undergo assessments to monitor disease-free survival and self-reported lymphoedema using specific questionnaires. Additional evaluations include arm function, quality of life, recurrence rates, survival, and cost-effectiveness analyses. The total study duration is planned for 120 months, including setup, recruitment, follow-up, analysis, and reporting.

Age: 18Years +All GendersPhase Not Applicable
98 locations
A

Actively Recruiting

Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.

Age: 28Days +All GendersPhase 3
408 locations
S

Actively Recruiting

Researchers are collecting detailed biological samples, imaging, environmental data, and patient-reported outcomes from cancer patients to support research aimed at understanding tumor biology and improving cancer care. This observational platform supports multiple projects focusing on different tumor types including thorax, head and neck, breast, gastrointestinal, genitourinary, central nervous system, and rare cancers. The goal is to enhance translational research, biomarker discovery, and clinical cancer study access. Participants provide tumor samples and clinical data which are analyzed using various genetic and molecular profiling techniques such as whole exome sequencing, RNA sequencing, and next-generation sequencing panels. Separate projects include studying young adults with rare cancers, molecular characterization of rare tumors, investigating molecular profiles in relation to environmental radon exposure, and assessing circulating tumor DNA as a marker for cancer recurrence. Participants are involved by providing biological material and clinical information, with data collected on tumor biology and treatment effects over five years. The study measures include understanding tumor biology, disease progression, treatment impact, biomarker identification, and matching patients to biomarker-driven clinical trials. Compliance with follow-up and consent are essential, and the study is designed to improve cancer patient care and research over an extended period.

Age: 12Years +All Genders
136 locations